Ludwig Institute for Cancer Research

Ludwig Institute for Cancer Research

Daniel K. Ludwig established the Ludwig Institute for Cancer Research in 1971. The shipping and resources fortune he accumulated funded an organization that now runs laboratories in North America, Europe, Asia, and other regions. The institute maintains its own administrative headquarters in New York and an international office in Zurich. The institute deploys capital through direct co-investments, SPVs, and a limited number of fund commitments. Asset classes include biotechnology startups, public equity positions in healthcare companies, and real estate holdings. Confirmed holdings include iTeos Therapeutics, Recepta Biopharma and UroGen Pharma. Geographic reach covers North America and Europe with additional activity in Asia, Africa, and South America. The LICR Fund, Inc. manages the endowment and supplies roughly 60 percent of the institute's annual research budget. The organization employs 501 people. It maintains the LICR Fund as its primary investment vehicle and has operated additional philanthropic structures such as the Virginia and D.K. Ludwig Fund for Cancer Research, which completed final distributions in 2014. April 2024: Sponsored and presented at the AACR Annual Meeting in San Diego on topics including cancer metabolism and immunotherapy. The institute's architecture differs from typical foundations because it combines an internal research network with an active investment subsidiary that retains ownership in portfolio companies and joint ventures. This model allows direct control over intellectual property and clinical translation rather than passive grant-making.